Literature DB >> 31803403

Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.

Vishnu C Damalanka1, Scott A Wildman2, James W Janetka1.   

Abstract

Matriptase and hepsin are type II transmembrane serine proteases (TTSPs). Along with related S1 trypsin like serine protease HGFA (hepatocyte growth factor activator), their unregulated proteolytic activity has been associated with cancer including tumor progression and metastasis. These three proteases have two substrates in common, hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), the ligands for MET and recepteur d'origine nantais (RON) receptor tyrosine kinases. Mechanism-based tetrapeptide and benzamidine inhibitors of these proteases have been shown to block HGF/MET and MSP/RON cancer cell signaling. Herein, we have rationally designed a new class of peptidomimetic hybrid small molecule piperidine carbamate dipeptide inhibitors comparable in potency to much larger tetrapeptides. We have identified multiple compounds which have potent activity against matriptase and hepsin and with excellent selectivity over the off-target serine proteases factor Xa and thrombin. This journal is © The Royal Society of Chemistry 2019.

Entities:  

Year:  2019        PMID: 31803403      PMCID: PMC6844230          DOI: 10.1039/c9md00234k

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  43 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 2.  Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).

Authors:  H Kataoka; H Itoh; R Hamasuna; J Y Meng; M Koono
Journal:  Hum Cell       Date:  2001-03       Impact factor: 4.174

Review 3.  The future of peptide-based drugs.

Authors:  David J Craik; David P Fairlie; Spiros Liras; David Price
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

Review 4.  Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.

Authors:  Vishnu C Damalanka; James W Janetka
Journal:  Future Med Chem       Date:  2019-04-04       Impact factor: 3.808

Review 5.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

6.  Proteolytic activation of pro-macrophage-stimulating protein by hepsin.

Authors:  Rajkumar Ganesan; Ganesh A Kolumam; S Jack Lin; Ming-Hong Xie; Lydia Santell; Thomas D Wu; Robert A Lazarus; Amitabha Chaudhuri; Daniel Kirchhofer
Journal:  Mol Cancer Res       Date:  2011-08-29       Impact factor: 5.852

7.  Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.

Authors:  Francisco M Franco; Darin E Jones; Peter K W Harris; Zhenfu Han; Scott A Wildman; Cassie M Jarvis; James W Janetka
Journal:  Bioorg Med Chem       Date:  2015-04-04       Impact factor: 3.641

8.  Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Authors:  Michael D Oberst; Michael D Johnson; Robert B Dickson; Chen-Yong Lin; Baljit Singh; Moira Stewart; Alastair Williams; Awatif al-Nafussi; John F Smyth; Hani Gabra; Grant C Sellar
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

9.  The protease inhibitor HAI-2, but not HAI-1, regulates matriptase activation and shedding through prostasin.

Authors:  Stine Friis; Katiuchia Uzzun Sales; Jeffrey Martin Schafer; Lotte K Vogel; Hiroaki Kataoka; Thomas H Bugge
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

10.  Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity.

Authors:  E Gak; W G Taylor; A M Chan; J S Rubin
Journal:  FEBS Lett       Date:  1992-10-12       Impact factor: 4.124

View more
  3 in total

1.  Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.

Authors:  Lukas Wettstein; Philip Maximilian Knaff; Christian Kersten; Patrick Müller; Tatjana Weil; Carina Conzelmann; Janis A Müller; Maximilian Brückner; Markus Hoffmann; Stefan Pöhlmann; Tanja Schirmeister; Katharina Landfester; Jan Münch; Volker Mailänder
Journal:  Commun Biol       Date:  2022-07-08

2.  Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.

Authors:  Vishnu C Damalanka; Jorine J L P Voss; Matthew W Mahoney; Tina Primeau; Shunqiang Li; Lidija Klampfer; James W Janetka
Journal:  J Med Chem       Date:  2021-12-13       Impact factor: 8.039

3.  A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.

Authors:  Matthew Mahoney; Vishnu C Damalanka; Michael A Tartell; Dong Hee Chung; André Luiz Lourenço; Dustin Pwee; Anne E Mayer Bridwell; Markus Hoffmann; Jorine Voss; Partha Karmakar; Nurit P Azouz; Andrea M Klingler; Paul W Rothlauf; Cassandra E Thompson; Melody Lee; Lidija Klampfer; Christina L Stallings; Marc E Rothenberg; Stefan Pöhlmann; Sean P J Whelan; Anthony J O'Donoghue; Charles S Craik; James W Janetka
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-26       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.